LYT-200

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Near Add Your Location

Sorting 9 by

Center of Excellence

Cedars-Sinai Medical Center - UCLA School of Medicine
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
  • Accepting patients
Miami Cancer Institute
Baptist Health South Florida
Miami, FL
  • Accepting patients
Norton Cancer Institute (St. Matthews)
St. Matthews Campus
Louisville, KY
  • Accepting patients

Center of Excellence

Massachusetts General Hospital
Boston, MA
  • Accepting patients

Center of Excellence

Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, MI
  • Accepting patients

Center of Excellence

Rutgers Cancer Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, NJ
  • Accepting patients
Lifespan Rhode Island Hospital
Providence, RI
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.